

DARRELL E. ISSA, CALIFORNIA  
CHAIRMAN

DAN BURTON, INDIANA  
JOHN L. MICA, FLORIDA  
TODD RUSSELL PLATTS, PENNSYLVANIA  
MICHAEL R. TURNER, OHIO  
PATRICK MCHENRY, NORTH CAROLINA  
JIM JORDAN, OHIO  
JASON CHAFFETZ, UTAH  
CONNIE MACK, FLORIDA  
TIM WALBERG, MICHIGAN  
JAMES LANKFORD, OKLAHOMA  
JUSTIN AMASH, MICHIGAN  
ANN MARIE BUERKLE, NEW YORK  
PAUL A. GOSAR, D.D.S., ARIZONA  
RAUL R. LABRADOR, IDAHO  
PATRICK MEEHAN, PENNSYLVANIA  
SCOTT DESJARLAIS, M.D., TENNESSEE  
JOE WALSH, ILLINOIS  
TREY GOWDY, SOUTH CAROLINA  
DENNIS A. ROSS, FLORIDA  
FRANK C. GUINTA, NEW HAMPSHIRE  
BLAKE FARENTHOLD, TEXAS  
MIKE KELLY, PENNSYLVANIA

LAWRENCE J. BRADY  
STAFF DIRECTOR

ONE HUNDRED TWELFTH CONGRESS

# Congress of the United States

## House of Representatives

COMMITTEE ON OVERSIGHT AND GOVERNMENT REFORM

2157 RAYBURN HOUSE OFFICE BUILDING

WASHINGTON, DC 20515-6143

MAJORITY (202) 225-5074

FACSIMILE (202) 225-3974

MINORITY (202) 225-5051

<http://oversight.house.gov>

ELIJAH E. CUMMINGS, MARYLAND  
RANKING MINORITY MEMBER

EDOLPHUS TOWNS, NEW YORK  
CAROLYN B. MALONEY, NEW YORK  
ELEANOR HOLMES NORTON,  
DISTRICT OF COLUMBIA  
DENNIS J. KUCINICH, OHIO  
JOHN F. TIERNEY, MASSACHUSETTS  
WM. LACY CLAY, MISSOURI  
STEPHEN F. LYNCH, MASSACHUSETTS  
JIM COOPER, TENNESSEE  
GERALD E. CONNOLLY, VIRGINIA  
MIKE QUIGLEY, ILLINOIS  
DANNY K. DAVIS, ILLINOIS  
BRUCE L. BRALEY, IOWA  
PETER WELCH, VERMONT  
JOHN A. YARMUTH, KENTUCKY  
CHRISTOPHER S. MURPHY, CONNECTICUT  
JACKIE SPEIER, CALIFORNIA

October 23, 2012

The Honorable Gene L. Dodaro  
Comptroller General of the United States  
U.S. Government Accountability Office  
441 G Street, NW  
Washington, DC 20548

Dear Mr. Dodaro:

According to the Centers for Disease Control and Prevention, 23 people have died and more than 280 people have been sickened with fungal meningitis linked to tainted vials of an injectable steroid produced by the New England Compounding Center (NECC), based in Framingham, Massachusetts.<sup>1</sup> As the number of cases continues to climb, news accounts report that NECC may have shipped more than 17,000 vials of this contaminated drug product to 23 states.<sup>2</sup>

It is our understanding that NECC was operating as a “pharmacy compounder,” meaning that it engaged in the process of mixing, combining, or altering ingredients for drug products on a customized basis for individual patients. While pharmacy compounders play an important role in providing patients with specialty products and dosages not easily available from manufacturers, the large volume of drug products sold by NECC raises questions about its proper classification. In addition, there are serious questions about the oversight of pharmacy compounders because they are subject to a patchwork of state and federal regulations, as well as conflicting legal opinions.

In 2003, the Government Accountability Office issued a report entitled *State and Federal Oversight of Drug Compounding by Pharmacies* that summarized the state of the law nine years ago. GAO reported:

---

<sup>1</sup> Centers for Disease Control and Prevention, *Multistate Fungal Meningitis Outbreak—Current Case Count* (online at [www.cdc.gov/HAI/outbreaks/meningitis-map.html#casecount\\_table](http://www.cdc.gov/HAI/outbreaks/meningitis-map.html#casecount_table)) (accessed Oct. 21, 2012).

<sup>2</sup> *In a Drug Linked to a Deadly Meningitis Outbreak, a Question of Oversight*, New York Times (Oct. 4, 2012) (online at [www.nytimes.com/2012/10/05/health/news-analysis-a-question-of-oversight-on-compounding-pharmacies.html](http://www.nytimes.com/2012/10/05/health/news-analysis-a-question-of-oversight-on-compounding-pharmacies.html)).

[T]he ability of states to oversee and ensure the quality and safety of compounded drugs may be affected by state-specific factors such as the resources available for inspections and enforcement. FDA maintains that drug compounding activities are generally subject to FDA oversight, including its authority to oversee the safety and quality of new drugs. In practice, however, the agency generally relies on states to regulate the limited compounding of drugs as part of the traditional practice of pharmacy. In 1997, the Congress passed a law exempting drug compounders that met certain criteria from key provisions of the Federal Food Drug and Cosmetic Act (FDCA), including the requirements for the approval of new drugs. These exemptions, however, were nullified in 2002 when the United States Supreme Court ruled part of the 1997 law to be an unconstitutional restriction on commercial speech, which resulted in the entire compounding section being declared invalid.<sup>3</sup>

We are writing to request that GAO update its work on pharmacy compounding in the following ways:


1. We ask that GAO work with state Boards of Pharmacy as part of its own review to determine the size of the pharmacy compounding industry, including the number of licensed pharmacies currently engaging in compounding, as well as general information about the volume of drug products they sell on an annual basis.
2. We ask that GAO conduct a review of state laws and regulatory authority over pharmacy compounders, as well as specific enforcement actions, and describe any challenges they face in effectively exercising authority over these entities.
3. We ask that GAO assess whether any gaps exist between state and federal regulatory systems in terms of the authorities exercised by state regulatory agencies and the Food and Drug Administration.

In addition to these issues, we would appreciate any additional information that GAO identifies as relevant to the administration and oversight of compound pharmacies. If you have any questions about this request, please contact Una Lee or Chris Knauer (202) 225-5051.

Sincerely,



Elijah Cummings  
Ranking Member  
Committee on Oversight and  
Government Reform



John Tierney  
Ranking Member  
Subcommittee on National Security,  
Homeland Defense and Foreign Operations

---

<sup>3</sup> Government Accountability Office, *State and Federal Oversight of Drug Compounding by Pharmacies* (Oct. 23, 2003) (GAO-04-195).

The Honorable Gene L. Dodaro

Page 3

cc: The Honorable Darrell E. Issa, Chairman  
Committee on Oversight and Government Reform

The Honorable Jason Chaffetz, Chairman  
Subcommittee on National Security, Homeland Defense and Foreign Operations

---